Advances in the development of biodegradable coronary stents: A translational perspective

Zong, Jiabin; He, Quanwei; Liu, Yu-Xiao; Qiu, Min; Wu, Jinjie; Hu, Bo

doi:10.1016/j.mtbio.2022.100368

Cited by 47 publications

(36 citation statements)

References 212 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors hypothesize the reason might be that Magmaris gives a shorter period of radial support (3 months) compared with absorb (6 months) and that this might lead to early recoil and collapse of the scaffold [27]. Several other bioresorbable platforms of either polymeric or metallic base have reached clinical trials, but balancing the radial strength with strut thickness remains an unresolved issue [28].…”

Section: Discussionmentioning

confidence: 99%

Everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stent in primary percutaneous coronary intervention of ST-segment elevation myocardial infarction: a randomized controlled trial

Eriksen

Neghabat

Saeed

et al. 2022

Coronary Artery Disease

View full text Add to dashboard Cite

Background Primary percutaneous coronary intervention with implantation of a metallic drug-eluting stent (DES) is the standard treatment for patients presenting with ST-elevation myocardial infarction (STEMI). Implantation of a bioresorbable scaffold (BRS) during STEMI represents a novel strategy without intravascular metal. Objective The aim of the study was to investigate 12-month healing response in an STEMI population after implantation of either the Absorb BRS or Xience DES (Abbott Vascular, USA). Methods The present trial was a prospective, randomized, controlled, nonblinded, noninferiority study with planned inclusion of 120 patients with STEMI. Patients were randomly assigned 1:1 to treatment with Absorb BRS or Xience DES. Implantation result and healing response were evaluated by angiography and optical coherence tomography (OCT) at baseline and 12-month follow-up. The primary endpoint was minimum flow area (MFA) assessed at 12 months. Coronary stent healing index (CSHI) was calculated from OCT images. Results Out of 66 included patients, 58 had follow-up OCT after 12 months, and 49 entered matched analysis. One death occurred in each group; none were stent-related. MFA was 5.13 ± 1.70 mm2 (95% CI, 4.44–5.82) in the BRS group compared with 6.30 ± 2.49 mm2 (95% CI, 5.22–7.37) (P = 0.06) in the DES group. Noninferiority could not be evaluated. CSHI for both groups had a median score of 3. Conclusion The DES group performed numerically better in primary and secondary endpoints, but the CSHI showed good stent healing in both groups.

show abstract

Section: Discussionmentioning

confidence: 99%

Everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stent in primary percutaneous coronary intervention of ST-segment elevation myocardial infarction: a randomized controlled trial

Eriksen

Neghabat

Saeed

et al. 2022

Coronary Artery Disease

View full text Add to dashboard Cite

show abstract

“…Untainted iron has a highly versatile modulus, which permits it to be utilized to make thinner struts. Whereas in‐vivo investigations showed that the iron stents have moderate degradation with endothelialization around the stent surface [78]. Coronary interventionalist have been demanding stents dimension with thinner struts.…”

Section: Metals Compatibility With the Imaging Devicementioning

confidence: 99%

Commercial pure titanium – A potential candidate for cardiovascular stent

Mohanta

Thirugnanam

2022

Materialwissenschaft Werkst

View full text Add to dashboard Cite

The most commonly used metal alloys for manufacturing coronary artery stents platforms are 316 L stainless steel, cobalt‐chromium, tantalum, and titanium alloys. Cobalt‐based alloys have several advantages: good flexibility, radial strength, and better radiopacity. But still, concern about their cytotoxicity exists. In comparison, commercially pure titanium possesses excellent corrosion resistance and biocompatibility properties. However, it faces a problem with its mechanical strength during the development of stents, thereby deteriorating its radial strength and making it a poor radiopaque element. This review illustrated the properties of titanium and strategies to overcome the disadvantages of commercially pure titanium: Surface treatment, polymer coating, and warm treatment. The importance of radiopacity and radial strength in post‐clinical imaging techniques and metals compatibility with the imaging devices are also introduced. The findings suggest that by controlling the springback effect via warm treatment, the elastic energy of commercially pure titanium decreases and hence, prevent the recoiling phenomenon. The reduction in the recoiling effect may improve the radial strength of titanium. This work has addressed the limitations of commercially pure titanium to overcome them in the future while developing as a cardiovascular stent.

show abstract

“…Percutaneous coronary intervention (PCI) has become the most common treatment for atherosclerotic stenosis. However, complications such as inflammation, intimal hyperplasia, and in-stent restenosis remain the leading causes of the failure of PCI treatment. , Drug-eluting stents can release drugs with anticoagulant and anti-inflammatory effects at the lesion, inhibiting the development of these complications . Therefore, the advent of drug-eluting stents is seen as a revolutionary development in interventional therapy.…”

Section: Introductionmentioning

confidence: 99%

Allicin-Loaded Intelligent Hydrogel Coating Improving Vascular Implant Performance

Han,

Lu,

Zou

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Coronary atherosclerosis is closely related to inflammation and oxidative stress. Owing to poor biocompatibility, lack of personalized treatment, and late toxic side effects, traditional drug-eluting stent intervention, releasing antiproliferative drugs, can delay endothelial repair and cause late thrombosis. The inflammation caused by atherosclerosis results in an acidic microenvironment and oxidative stress, which can be considered as triggers for precise and intelligent treatment. Here, we used catechol hyaluronic acid (C-HA) and cystamine (Cys) to prepare C-HA-Cys hydrogel coatings by amide reaction. The H 2 S-releasing donor allicin was loaded in the hydrogel to form an intelligent biomimetic coating. The disulfide bond of Cys made the crosslinked network redox-responsive to the inflammation and oxidative stress in the microenvironment by releasing the drug and H 2 S intelligently to combat the side effects of stent implantation. This study evaluated the hemocompatibility, anti-inflammatory capacity, vascular wall cytocompatibility, and in vivo histocompatibility of this intelligent hydrogel coating. Furthermore, the effect of H 2 S released from the coating on atherosclerosis-related signaling pathways such as CD31 and cystathionine γ-lyase (CSE), CD36, and ACAT-1 was investigated. Our results indicate that the C-HA-Cys-Allicin hydrogel coating could be manufactured on the surface of vascular interventional devices to achieve a precise response to the microenvironment of the lesion to release drug, which can attain the purpose of prevention of in-stent restenosis and ensure the effectiveness and safety of the application of interventional devices.

show abstract

Advances in the development of biodegradable coronary stents: A translational perspective

Cited by 47 publications

References 212 publications

Everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stent in primary percutaneous coronary intervention of ST-segment elevation myocardial infarction: a randomized controlled trial

Everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stent in primary percutaneous coronary intervention of ST-segment elevation myocardial infarction: a randomized controlled trial

Commercial pure titanium – A potential candidate for cardiovascular stent

Allicin-Loaded Intelligent Hydrogel Coating Improving Vascular Implant Performance

Contact Info

Product

Resources

About